Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare

SIMPLE SUMMARY: Hormonal therapy with long-acting luteinizing hormone-releasing hormone (LHRH) for metastatic hormone-sensitive prostate cancer (MHSPC) results initially in testosterone flare followed by testosterone deprivation. Docetaxel is a chemotherapy that is effective against prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Nicola J., Sun, Kai, Scanlon, Karen M., Mishra, Mark V., Molitoris, Jason K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870394/
https://www.ncbi.nlm.nih.gov/pubmed/35205611
http://dx.doi.org/10.3390/cancers14040864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870394/
https://www.ncbi.nlm.nih.gov/pubmed/35205611
http://dx.doi.org/10.3390/cancers14040864

Ejemplares similares